cannabidiol and Arthritis

cannabidiol has been researched along with Arthritis* in 11 studies

Reviews

1 review(s) available for cannabidiol and Arthritis

ArticleYear
Effects of Cannabidiol in Inflammation: A Review of Pre-clinical and Clinical Findings.
    Prague medical report, 2023, Volume: 124, Issue:3

    Cannabidiol (CBD) is the second most abundant component of the plant Cannabis sativa. Currently, CBD is approved for Lennox-Gastaut and Dravet syndrome and newly for tuberous sclerosis complex. However, based on the available data, CBD migth have a broad spectrum of potential therapeutic uses. Therefore, the aim of this review was to summarize the evidence on the effects of CBD on pain and inflammation of various causes. PubMed and Web of Science databases were searched until January 2023. The medical keyword term "cannabidiol" was combined with "pain", "arthritis", and "inflammation". Based on the initial search for these terms, 9, 5, and 5 relevant publications have been selected. Based on the available data, it is not possible to draw a clear conclusion about the effect of CBD to releave pain, because each study used a different route of administration or treatment regimen. The studies also differed in etiopathogenesis of pain (chronic, neuropathic, and possibly inflammatory pain), and in general included only small number of subjects. In case of anti-inflammatory qualities of CBD, its effect on the intestinal system is negligible. On the other hand, positive treatment results were observed in all publications dealing with the effect of CBD on arthritis.

    Topics: Arthritis; Cannabidiol; Epilepsies, Myoclonic; Humans; Inflammation; Pain

2023

Trials

1 trial(s) available for cannabidiol and Arthritis

ArticleYear
A Randomized Controlled Trial of Topical Cannabidiol for the Treatment of Thumb Basal Joint Arthritis.
    The Journal of hand surgery, 2022, Volume: 47, Issue:7

    Since the passage of the Agricultural Improvement Act of 2018, hand surgeons have increasingly encountered patients seeking counseling on over-the-counter, topical cannabidiol (CBD) for the treatment of pain. To this end, we designed a human clinical trial to investigate the therapeutic potential of CBD for the treatment of pain associated with thumb basal joint arthritis.. Following Food and Drug Administration and institutional approval, a phase 1 skin test was completed with 10 healthy participants monitored for 1 week after twice-daily application of 1 mL of topical CBD (6.2 mg/mL) with shea butter. After no adverse events were identified, we proceeded with a phase 2, double-blinded, randomized controlled trial. Eighteen participants with symptomatic thumb basal joint arthritis were randomized to 2 weeks of twice-daily treatment with CBD (6.2 mg/mL CBD with shea butter) or shea butter alone, followed by a 1-week washout period and then crossover for 2 weeks with the other treatment. Safety data and physical examination measurements were obtained at baseline and after completion of each treatment arm.. Cannabidiol treatment resulted in improvements from baseline among patient-reported outcome measures, including Visual Analog Scale pain; Disabilities of the Arm, Shoulder, and Hand; and Single Assessment Numeric Evaluation scores, compared to the control arm during the study period. There were similar physical parameters identified with range of motion, grip, and pinch strength.. In this single-center, randomized controlled trial, topical CBD treatment demonstrated significant improvements in thumb basal joint arthritis-related pain and disability without adverse events.. Therapeutic II.

    Topics: Arthritis; Cannabidiol; Hand Joints; Humans; Pain; Thumb

2022

Other Studies

9 other study(ies) available for cannabidiol and Arthritis

ArticleYear
The Mechanism of Cannabichromene and Cannabidiol Alone Versus in Combination in the Alleviation of Arthritis-Related Inflammation.
    Annals of plastic surgery, 2023, 06-01, Volume: 90, Issue:6S Suppl 4

    Patients suffering from arthritis have limited treatment options for nonoperative management. In search of pain relief, patients have been taking over-the-counter cannabinoids. Cannabidiol (CBD) and cannabichromene (CBC) are minor cannabinoids with reported analgesic and anti-inflammatory properties and have been implicated as potential therapeutics for arthritis-related pain. To this end, we utilized a murine model to investigate the effectiveness of and mechanism by which CBC alone, CBD alone, or CBD and CBC in combination may provide a reduction in arthritis-associated inflammation.. Forty-eight mice were included in the study, which were separated into 4 groups: control group (n = 12), treatment with CBD alone (n = 12), treatment with CBC alone (n = 12), and treatment with CBD + CBC (n = 12). We induced inflammation in each mouse utilizing the collagen-induced arthritis model. At scheduled timepoints, mice were clinically assessed for weight gain, swelling, and arthritis severity. In addition, inflammation-associated serum cytokine levels were analyzed for each animal.. Thirty-five of 48 mice survived the duration of the study resulting in the following group numbers: control group (n = 8), treatment with CBD alone (n = 9), treatment with CBC alone (n = 9), and treatment with CBD + CBC (n = 9). Animals treated with CBC and CBD + CBC showed significant weight gain between 3 and 5 weeks. Irrespective of treatment, regression analysis comparing all cytokine measurement and physical outcomes found a significant positive correlation between levels of 5 individual cytokines and both arthritis scores and swelling. Animals treated with CBD + CBC showed a significant decrease in swelling between 3 and 5 weeks compared with the control group. Cannabinoid treatment selectively affected the gene expression of eotaxin and lipopolysaccharide-induced CXC chemokine with combined treatment of CBC + CBD.. Treatment with cannabinoids resulted in decreased clinical markers of inflammation. Further, the anti-inflammatory effect of CBC and CBD in conjunction was associated with a greater anti-inflammatory effect than either minor cannabinoid alone. Future work will elucidate the possibility of synergistic or entourage effects of minor cannabinoids used in combination for the treatment of arthritis-related pain and inflammation.

    Topics: Animals; Arthritis; Cannabidiol; Cannabinoids; Cytokines; Inflammation; Mice; Pain

2023
Anti-Inflammatory and Analgesic Properties of the Cannabis Terpene Myrcene in Rat Adjuvant Monoarthritis.
    International journal of molecular sciences, 2022, Jul-17, Volume: 23, Issue:14

    Topics: Acyclic Monoterpenes; Alkenes; Analgesics; Animals; Anti-Inflammatory Agents; Arthralgia; Arthritis; Cannabidiol; Cannabinoid Receptor Agonists; Cannabis; Chronic Pain; Hallucinogens; Inflammation; Male; Rats; Rats, Wistar; Terpenes

2022
The Quality of Online Resources Available to Patients Regarding Cannabidiol for Symptomatic Relief of Hip or Knee Arthritis is Poor.
    Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews, 2021, 01-22, Volume: 5, Issue:1

    This study aimed to assess the quality of online resources pertaining to cannabidiol (CBD) for the nonoperative management of hip and knee arthritis.. Websites were identified on the three most popular global search engines using terms relevant to CBD, hip or knee pain, and arthritis. Websites were scored based on a 25-point scale regarding diagnosis, evaluation, and treatment of hip and knee pathologies.. The initial search yielded 287 results, and 94 websites were analyzed after meeting inclusion criteria. The average Flesch-Kincaid reading level was 48, corresponding to a college education level. Mean website score was poor at 7.46 (SD 3.51) of 25 (29.8%). Websites published by physicians had statistically higher scores (P = 0.03).. Many online resources regarding CBD use for hip and knee arthritis are available; however, the readability is more advanced than recommended by the National Institutes of Health. Very few resources are sponsored by physicians or professional organizations, and many are overtly sales oriented. Patients should be counseled that the information available online on this topic is generally unreliable. Surgeons and professional health organizations should play a stronger role in providing balanced resources to patients regarding CBD use for hip and knee arthritis.

    Topics: Arthritis; Cannabidiol; Comprehension; Humans; Search Engine

2021
New Arthritis Foundation Guidelines On CBD Use Could Be First Of Many More To Come.
    Alternative therapies in health and medicine, 2020, Volume: 26, Issue:S1

    No Abstract Available.

    Topics: Arthritis; Cannabidiol; Cannabis; Humans

2020
Transdermal cannabidiol reduces inflammation and pain-related behaviours in a rat model of arthritis.
    European journal of pain (London, England), 2016, Volume: 20, Issue:6

    Current arthritis treatments often have side-effects attributable to active compounds as well as route of administration. Cannabidiol (CBD) attenuates inflammation and pain without side-effects, but CBD is hydrophobic and has poor oral bioavailability. Topical drug application avoids gastrointestinal administration, first pass metabolism, providing more constant plasma levels.. This study examined efficacy of transdermal CBD for reduction in inflammation and pain, assessing any adverse effects in a rat complete Freund's adjuvant-induced monoarthritic knee joint model. CBD gels (0.6, 3.1, 6.2 or 62.3 mg/day) were applied for 4 consecutive days after arthritis induction. Joint circumference and immune cell invasion in histological sections were measured to indicate level of inflammation. Paw withdrawal latency (PWL) in response to noxious heat stimulation determined nociceptive sensitization, and exploratory behaviour ascertained animal's activity level.. Measurement of plasma CBD concentration provided by transdermal absorption revealed linearity with 0.6-6.2 mg/day doses. Transdermal CBD gel significantly reduced joint swelling, limb posture scores as a rating of spontaneous pain, immune cell infiltration and thickening of the synovial membrane in a dose-dependent manner. PWL recovered to near baseline level. Immunohistochemical analysis of spinal cord (CGRP, OX42) and dorsal root ganglia (TNFα) revealed dose-dependent reductions of pro-inflammatory biomarkers. Results showed 6.2 and 62 mg/day were effective doses. Exploratory behaviour was not altered by CBD indicating limited effect on higher brain function.. These data indicate that topical CBD application has therapeutic potential for relief of arthritis pain-related behaviours and inflammation without evident side-effects.

    Topics: Administration, Cutaneous; Animals; Arthritis; Behavior, Animal; Cannabidiol; Disease Models, Animal; Freund's Adjuvant; Male; Pain; Rats; Rats, Sprague-Dawley

2016
The cation channel Trpv2 is a new suppressor of arthritis severity, joint damage, and synovial fibroblast invasion.
    Clinical immunology (Orlando, Fla.), 2015, Volume: 158, Issue:2

    Little is known about the regulation of arthritis severity and joint damage in rheumatoid arthritis (RA). Fibroblast-like synoviocytes (FLS) have a central role in joint damage and express increased levels of the cation channel Trpv2. We aimed at determining the role of Trpv2 in arthritis. Treatment with Trpv2-specific agonists decreased the in vitro invasiveness of FLS from RA patients and arthritic rats and mice. Trpv2 stimulation suppressed IL-1β-induced expression of MMP-2 and MMP-3. Trpv2 agonists, including the new and more potent LER13, significantly reduced disease severity in KRN serum- and collagen-induced arthritis, and reduced histologic joint damage, synovial inflammation, and synovial blood vessel numbers suggesting anti-angiogenic activity. In this first in vivo use of Trpv2 agonists we discovered a new central role for Trpv2 in arthritis. These new compounds have the potential to become new therapies for RA and other diseases associated with inflammation, invasion, and angiogenesis.

    Topics: Animals; Arthritis; Arthritis, Rheumatoid; Calcium Channels; Cannabidiol; Cannabinoids; Collagen; Fibroblasts; Humans; Mice; Rats; RNA Interference; RNA, Small Interfering; Synovial Membrane; Terpenes; Tissue Culture Techniques; TRPV Cation Channels

2015
The abnormal cannabidiol analogue O-1602 reduces nociception in a rat model of acute arthritis via the putative cannabinoid receptor GPR55.
    Neuroscience letters, 2011, Aug-01, Volume: 500, Issue:1

    Cannabinoids classically act via CB₁ and CB₂ receptors to modulate nociception; however, recent findings suggest that some cannabinoids bind to atypical receptors. One such receptor is GPR55 which is activated by the abnormal cannabidiol analogue O-1602. This study investigated whether the synthetic GPR55 agonist O-1602 can alter joint nociception in a rat model of acute joint inflammation. Acute (24 h) inflammatory joint pain was induced in male Wistar rats by intra-articular injection of 2% kaolin and 2% carrageenan. Single unit extracellular recordings were made from arthritic joint afferents in response to mechanical rotation of the knee. Peripheral administration of O-1602 significantly reduced movement-evoked firing of nociceptive C fibres and this effect was blocked by the GPR55 receptor antagonist O-1918. Co-administration of the CB₁ and CB₂ antagonists (AM281 and AM630 respectively) had no effect on O-1602 responses. This study clearly shows that atypical cannabinoid receptors are involved in joint nociception and these novel targets may be advantageous for the treatment of inflammatory pain.

    Topics: Action Potentials; Acute Disease; Afferent Pathways; Animals; Arthritis; Cannabidiol; Carrageenan; Hindlimb; Joints; Kaolin; Male; Movement; Nerve Fibers, Unmyelinated; Nociception; Rats; Rats, Wistar; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Receptors, G-Protein-Coupled

2011
The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis.
    Proceedings of the National Academy of Sciences of the United States of America, 2000, Aug-15, Volume: 97, Issue:17

    The therapeutic potential of cannabidiol (CBD), the major nonpsychoactive component of cannabis, was explored in murine collagen-induced arthritis (CIA). CIA was elicited by immunizing DBA/1 mice with type II collagen (CII) in complete Freund's adjuvant. The CII used was either bovine or murine, resulting in classical acute CIA or in chronic relapsing CIA, respectively. CBD was administered after onset of clinical symptoms, and in both models of arthritis the treatment effectively blocked progression of arthritis. CBD was equally effective when administered i.p. or orally. The dose dependency showed a bell-shaped curve, with an optimal effect at 5 mg/kg per day i.p. or 25 mg/kg per day orally. Clinical improvement was associated with protection of the joints against severe damage. Ex vivo, draining lymph node cells from CBD-treated mice showed a diminished CII-specific proliferation and IFN-gamma production, as well as a decreased release of tumor necrosis factor by knee synovial cells. In vitro effects of CBD included a dose-dependent suppression of lymphocyte proliferation, both mitogen-stimulated and antigen-specific, and the blockade of the Zymosan-triggered reactive oxygen burst by peritoneal granulocytes. It also was found that CBD administration was capable of blocking the lipopolysaccharide-induced rise in serum tumor necrosis factor in C57/BL mice. Taken together, these data show that CBD, through its combined immunosuppressive and anti-inflammatory actions, has a potent anti-arthritic effect in CIA.

    Topics: Administration, Oral; Animals; Arthritis; Cannabidiol; Cannabis; Cattle; Cell Division; Collagen; Disease Models, Animal; Dose-Response Relationship, Drug; Granulocytes; Hindlimb; Interferon-gamma; Joints; Lipopolysaccharides; Lymph Nodes; Lymphocyte Activation; Male; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Peritoneum; Reactive Oxygen Species; Synovial Fluid; Th1 Cells; Tumor Necrosis Factor-alpha; Zymosan

2000
Immunoactive cannabinoids: therapeutic prospects for marijuana constituents.
    Proceedings of the National Academy of Sciences of the United States of America, 2000, Aug-15, Volume: 97, Issue:17

    Topics: Animals; Arthritis; Cannabidiol; Cannabis; Complementary Therapies; Immune System; Ligands; Mice; Phytotherapy; Receptors, Cannabinoid; Receptors, Drug

2000